Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL367 Target Snapshot

Leishmania donovani · ORGANISM · Leishmania donovani

Back to Search Search this target Browse approvals Evidence Card
78,069Compounds
2,138Assays
56Approved Drugs
13,038.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leishmania donovani as ChEMBL target CHEMBL367. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leishmania donovani
ORGANISM · Leishmania donovani
As of 2026-09-13
ChEMBL target ID
CHEMBL367
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Leishmania donovani still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLeishmania donovani
Target TypeORGANISM
OrganismLeishmania donovani
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLeishmania donovani
UniProt AccessionN/A

Leishmania donovani

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Leishmania donovani.

Review nameLeishmania donovani
OrganismLeishmania donovani
Clinical Profile

Clinical Phase Distribution

56
Approved
17
Phase III
18
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC5011,928.0
KI9.0
EC501,101.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL218650 9.92 IC50 0.12 Approved
CHEMBL125 9.57 IC50 0.27 Approved
CHEMBL4763675 9.0 IC50 1.0 Preclinical
CHEMBL231385 8.82 IC50 1.5 Preclinical
CHEMBL55 8.72 IC50 1.9 Approved
CHEMBL520624 8.7 IC50 2.0 Preclinical
CHEMBL482925 8.7 IC50 2.0 Preclinical
CHEMBL484303 8.7 IC50 2.0 Preclinical
CHEMBL231386 8.6 IC50 2.5 Preclinical
CHEMBL24057 8.55 IC50 2.8 Preclinical
Distribution

pChEMBL Value Distribution

2018
5.0
1309
5.5
717
6.0
330
6.5
184
7.0
91
7.5
26
8.0
9
8.5
1
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

NIFURTIMOX
CHEMBL290960
Approved 2020
Properties Compare Identifier
DELAMANID
CHEMBL218650
Approved 2014
Properties Compare Identifier
MILTEFOSINE
CHEMBL125
Approved 2014
Properties Compare Identifier
CLOFAZIMINE
CHEMBL1292
Approved 1986
Properties Compare Identifier
PENTAMIDINE
CHEMBL55
Approved 1984
Properties Compare Identifier
NICLOSAMIDE
CHEMBL1448
Approved 1982
Properties Compare Identifier
KETOCONAZOLE
CHEMBL157101
Approved 1981
Properties Compare Identifier
PAROMOMYCIN
CHEMBL370143
Approved 1969
Properties Compare Identifier
AMPHOTERICIN B
CHEMBL267345
Approved 1964
Properties Compare Identifier
FURAZOLIDONE
CHEMBL1103
Approved 1958
Properties Compare Identifier
Assay Landscape

Assay Landscape

2,199
Total Assays
5,279
Tested Compounds
2
Assay Types
Functional — 2,178 assays, 5,279 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 2,107 5,034 5.3
assay format 47 134 5.5
cell-based format 24 111 6.4
ADME — 21 assays, 16 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 21 16 4.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine